MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.81
+0.82
+6.31%
Closed 19:53 08/10 EDT
OPEN
13.05
PREV CLOSE
12.99
HIGH
14.21
LOW
13.02
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
14.21
52 WEEK LOW
3.790
MARKET CAP
1.21B
P/E (TTM)
-6.3175
1D
5D
1M
3M
1Y
5Y
Cogent Biosciences GAAP EPS of -$0.71 misses by $0.05
Cogent Biosciences press release (<span class="tic...
Seekingalpha · 1d ago
Cogent Biosciences Q2 Loss Widens
Cogent Biosciences Q2 Loss Widens
MT Newswires · 2d ago
--SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outperform Rating
--SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outperform Rating
MT Newswires · 2d ago
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 6d ago
Guggenheim Starts Cogent Biosciences at Buy With $15 Price Target
MT Newswires · 06/28 07:43
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Benzinga · 06/21 08:44
Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions?
The big shareholder groups in Cogent Biosciences, Inc. ( NASDAQ:COGT ) have power over the company. Insiders often own...
Simply Wall St. · 06/20 15:09
BRIEF-Cogent Biosciences Announces Closing Of Upsized Public Offering Of Common Stock And Pre-Funded Warrants And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
reuters.com · 06/16 20:31
More
No Data
Learn about the latest financial forecast of COGT. Analyze the recent business situations of Cogent Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

62.50%Strong Buy
37.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average COGT stock price target is 20.75 with a high estimate of 31.00 and a low estimate of 15.00.
High31.00
Average20.75
Low15.00
Current 13.81
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 51.78M
% Owned: 58.94%
Shares Outstanding: 87.85M
TypeInstitutionsShares
Increased
18
3.01M
New
15
3.55M
Decreased
30
1.06M
Sold Out
10
3.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Peter Harwin
President/Chief Executive Officer/Director
Andrew Robbins
Chief Financial Officer/Chief Accounting Officer
John Green
Chief Scientific Officer
John Robinson
Other
Jessica Sachs
Secretary
Evan Kearns
Independent Director
Chris Cain
Independent Director
Karen Ferrante
Independent Director
Arlene Morris
Independent Director
Matthew Ros
Independent Director
Todd Shegog
No Data
No Data
About COGT
Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.

Webull offers kinds of Cogent Biosciences Inc stock information, including NASDAQ:COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.